Epidemiologic and clinical updates on impulse control disorders: a critical review

  • Bernardo Dell’Osso
  • A. Carlo Altamura
  • Andrea Allen
  • Donatella Marazziti
  • Eric Hollander
Open Access


The article reviews the current knowledge about the impulse control disorders (ICDs) with specific emphasis on epidemiological and pharmacological advances. In addition to the traditional ICDs present in the DSM-IV—pathological gambling, trichotillomania, kleptomania, pyromania and intermittent explosive disorder—a brief description of the new proposed ICDs—compulsive–impulsive (C–I) Internet usage disorder, C–I sexual behaviors, C–I skin picking and C–I shopping—is provided. Specifically, the article summarizes the phenomenology, epidemiology and comorbidity of the ICDs. Particular attention is paid to the relationship between ICDs and obsessive–compulsive disorder (OCD). Finally, current pharmacological options for treating ICDs are presented and discussed.


impulse control disorders (ICDs) obsessive–compulsive disorder (OCD) pathological gambling (PG) kleptomania compulsive–impulsive (C–I) shopping trichotillomania (TTM) intermittent explosive disorder (IED) C–I Internet usage disorder C–I sexual behaviors (C–ISBs) C–I skin picking pyromania 


Since the early 1990s, some researchers have suggested that the impulse control disorders (ICDs) might be conceptualized as a part of an obsessive–compulsive spectrum based on their clinical characteristics, familial transmission, and response to both pharmacological and psychosocial treatment interventions [1, 2, 3]. Over a decade of study and scientific developments have led a DSM-V task force to consider two important changes: separating obsessive–compulsive disorder (OCD) from the anxiety disorders and placing it in an autonomous category—the obsessive–compulsive spectrum disorders (OCSD); and creating several new autonomous disorders from those currently subsumed under ICDs not otherwise specified (ICD-NOS) [4], specifically including four new impulsive disorders, compulsive–impulsive (C–I) Internet usage disorder C–I sexual behaviors, C–I skin picking and C–I shopping. They are called compulsive–impulsive disorders due to the impulsive features (arousal) that initiate the behavior, and the compulsive drive that causes the behaviors to persist over time.

The relationship between OCD and the OC spectrum has been supported by studies over the past decade, although recent studies have also supported additional models. Recent neuroimaging (PET, fMRI etc.) and genetics studies have increased understanding of the biological and neuroanatomical characteristics of the ICDs and have supported both the OC spectrum model and suggested other models [5, 6]. The pharmacological options, moreover, have been expanded based on recent research; traditional treatment with the serotonin reuptake inhibitors (SRIs) supported the OC spectrum model, but recent research demonstrating the efficacy of different pharmacological interventions suggests that additional systems are involved and other models may be useful. For example, the efficacy of pharmacotherapies acting on different systems of neuromediators (opioid antagonists, mood stabilizers, dopamine reuptake inhibitors), support different theoretical models for the ICDs and make clear that it is valuable to look at the ICDs from different theoretical perspectives that suggest different mechanisms might be important and raise new research questions.

ICDs’ phenomenology, epidemiology and relationship with OCD

ICDs are characterized by repetitive behaviors and impaired inhibition of these behaviors. Important defining criteria for these disorders include:
  1. 1.

    The failure to resist an impulse to perform some act that is harmful to the individual or others;

  2. 2.

    An increasing sense of arousal or tension prior to committing or engaging in the act;

  3. 3.

    An experience of either pleasure, gratification, or release of tension at the time of committing the act.


In addition, there is usually a pattern of engaging in the abnormal behavior in spite of adverse consequences (e.g., criminal changes, impairment of normal functioning, etc.). To demonstrate that a relationship exists between ICDs and OCD, there should be evidence that OCD is overrepresented in patients with ICDs and/or that ICDs are overrepresented in patients with OCD. Studies examining rates of OCD in patients with ICDs have reported inconsistent results, with some ICDs showing relatively high rates of comorbidity with OCD (trichotillomania, CI-shopping), and others demonstrating low rates (intermittent explosive disorder, pathological gambling, and C–I sexual behaviors).

Pathological gambling (PG) is an impulse control disorder not otherwise specified (ICD-NOS) [4] that is characterized by recurrent and maladaptive patterns of gambling behavior that significantly disrupts the patient’s functioning in the personal, familial, or vocational spheres. Recent studies suggest that the prevalence of PG is between 1% and 3% of the adult population [7, 8], and a meta-analysis [9] estimated that 86% of the population of the USA are recreational gamblers (Table 1). The disorder usually starts during adolescence with a prevalence of approximately 4–7% in this population. However, over the last decade, there has been an unprecedented expansion of legalized gambling throughout North America, and, as a result, the prevalence of PG can be expected to increase. The disorder is currently more common in men than in women. Recent national studies on PG prevalence have also been conducted in New Zealand [10, 11, 12], Sweden [13, 14], Switzerland [15], Australia [16] and Great Britain [17], and despite the use of different methodologies and variable technical quality, problem gambling prevalence studies have shown a high degree of consistency in their general findings.
Table 1

Prevalence estimates of impulse control disorders

Impulse control disorder


Type of community

Prevalence reported

Pathological Gambling

Gerstein et al. (1999)

Adult population



Welte et al. (2001)

Adult population



Christenson et al. (1991)

College students

1.5% males; 3.4 females


Kosky and Silburn (1984)

Children and adolescents



Kolko et al. (1988)

Children and adolescents


Jacobson (1995)

Children and adolescents


Intermittent Explosive Disorder

Monopolis and Lion (1983)

Psychiatric surveys


Coccaro et al. (2004)

Adult population

Lifetime 11.1%; 1 month 3.2%


Goldman (1991)

Adult population


C–I Internet Usage Disorder

C–I Shopping

Black et al. (2001)

Adult population


C–I Skin Picking

Doran et al. (1985)

Dermatologic patients


Gupta et al. (1986)

Dermatologic patients

C–I Sexual Behaviors

Shaffer and Zimmerman (1990)

Adult population


Coleman, 1991

Adult population

A crucial issue to consider is the high rate of comorbidity among pathological gamblers. Patients with PG, at least those seeking treatment, have been found to score significantly higher than control populations on measures of depression [18], and have high incidences of various psychiatric disorders, including bipolar, anxiety and substance use disorders [19]. This frequent comorbidity is not surprising given the psychopathological core features of PG: impulsivity, compulsive drive to gamble, addictive features such as withdrawal symptoms during gambling abstinence, and bipolar features such as urges, pleasure seeking and decreased judgment due to unrealistic appraisal of the individuals’ own abilities. Several authors have noted the link between various core features of PG and neurobiological characteristics or treatment-response, and have conceptualized PG according to different models, thus placing it on different spectrums with the main psychiatric disorders of reference being OCD [1], addictive disorders [20], and affective disorders [21]. These models provide the theoretical rationale for the use of specific pharmacological treatments in PG. In addition, the models and related research findings may also suggest the presence of specific subgroups of patients with similar core features, comorbidity profiles and treatment-response within the population of pathological gamblers [22, 23]. The relationship between PG and OCD has allowed PG to be conceptualized as an OC spectrum disorder, within the impulsive cluster [1]. Patients with OC spectrum disorders, in fact, experience unpleasant feelings and physiological activation that result in an intense desire to perform a specific behavior in order to relieve the unpleasant feelings [24, 25]; this is the case in PG. In addition, a reduced capacity to resist gambling thoughts and urges leads to excessive gambling, in particular in the advanced phases of the disorder [26]. However, these patients differ from patients with OCD in important ways. Gambling behavior and thoughts are often experienced by these patients as ego-syntonic, while OCD obsessions and compulsions are generally ego-dystonic. In addition, the excessive doubt frequently experienced by OCD patients [24, 27, 28], as well as their harm avoidance, risk aversion and anticipatory anxiety [29], are not characteristic of pathological gamblers. OC spectrum disorders differ along the dimension of risk aversion vs. risk taking; the compulsive disorders are characterized by an overestimation of harm and by risk aversion while the impulsive disorders are characterized by an underestimation of risk and by risk seeking. Recently, the rate of comorbid OCD in individuals with PG was found to range from 1% to 20% [30] (Table 2).
Table 2

OCD rates in impulse control disorders

Impulse control disorder


Rates of OCD

Pathological Gambling

Argo and Black (2004)



Christenson and Mansueto (1999)



Intermittent Explosive Disorder

McElroy et al. (1998)



Presta et al. (2002)


C–I Internet Usage Disorder

Black et al. (1999)

0% current; 10% lifetime

Shapira et al. (2000)

15% current; 20% lifetime

C–I Shopping

Christenson et al. (1994)


McElroy et al. (1998)

C–I Skin Picking

Simeon et al. (1997)


Arnold et al. (1998)

Wilhelm et al. (1999)

C–I Sexual Behaviors

Kafka and Prentky (1994)


Black et al. (1997)

Patients afflicted with trichotillomania (TTM) describe an overwhelming urge to pluck out specific hairs; when they do so, the anxiety is momentarily relieved but is quickly replaced by another compulsive urge to pluck and even greater anxiety [31]. The exact prevalence of TTM is unknown; however, estimates from university surveys suggest that 1.5% of males and 3.4% of females endorse clinically significant hair pulling, with .6% endorsing all diagnostic criteria of TTM [32] (Table 1). The prevalence of non-clinical hair pulling behavior is even higher, up to 15.3%, in university surveys [33] (Table 1). In describing the phenomenological similarities between OCD and TTM, Swedo [34] highlighted the egodystonic feeling and the resistance experienced by patients with TTM and OCD. In addition, patients with TTM recognize the behavior as senseless, undesirable and performed in response to increasing anxiety, with resultant tension relief. Furthermore, a higher than normal incidence of both OCD and TTM has been reported in first-degree relatives of patients with TTM [35], and comorbidity data also support a relationship between OCD and TTM [36, 37] (Table 2). However, recent investigations [38, 39] have also included TTM in a spectrum of self-injurious behaviors (SIBs), including C–I skin picking, and underscored the phenomenological link among these SIBs and the differences between TTM and OCD [39].

In pyromania there is impulsive, repetitive, deliberate fire setting without external reward (e.g., arson for money, revenge, as a political act). There are very few community sample studies of firesetting, which is understandable since it is illegal and thus likely to be kept secret. The majority of epidemiological studies have focused on pyromania in childhood and adolescence and have reported the prevalence to be between 2.4% [40] and 3.5% [41, 42] (Table 1). In addition, several lines of evidence indicate that adolescent boys may be at higher risk for firesetting than adolescent girls [43, 44]. Among juveniles, firesetting is more prevalent in males than females, peaking between 12 years and 14 years [45]. Sixty percent of all fires in large U.S. cities are lit by individuals between 11 years and 18 years [46]. Besides young age, features such as temperament, parental psychopathology, social and environmental factors, and possible neurochemical predispositions [47] have been hypothesized to cause childhood pyromania. Some authors have noted a close link between firesetting and aggression [48] and between firesetting and antisocial behavior [49]. In addition, published data have shown high rates of conduct disorder among young arsonists [50]. Recent findings, moreover, revealed associations between firesetting and shyness, aggression and peer rejection [51]. No published studies of the relationship between pyromania and OCD in terms of comorbidity or family history are available.

Intermittent explosive disorder (IED) is characterized by recurrent episodes of aggressive behavior that is out of proportion to psychosocial stressors and/or provocation and that is not better accounted by another mental disorder, comorbid medical conditions, or the physiologic effects of a pharmacologic agent or other substance with psychotropic properties [4]. Despite its inclusion in DSM for more than two decades, there are few studies of the lifetime prevalence of IED in either psychiatric or community settings. Clinical surveys of psychiatric inpatients [52], and clinical treatment studies on IED [53] had found rates of IED in psychiatric settings ranging from 1% to 2%. Recently, however, Coccaro and colleagues reported much higher rates of IED, 11.1% lifetime prevalence and 3.2% 1-month prevalence, in a community sample of 253 individuals [54] (Table 1). Based on these data, the authors estimated there are 1.4 million individuals with current IED in the US and 10 million with lifetime IED. As the authors suggested, prevalence rates so much higher than prior findings may reflect the changes in diagnostic criteria of IED from DSM-III [55] to DSM-IV [4] as well as the changes recently proposed in the development of research criteria for IED [56, 57]. A study by McElroy and colleagues reported rates of OCD in individuals with IED around 22% [58] (Table 2); recent studies investigating the rates of IED in patients with OCD have given lower estimates [59, 60, 61].

Kleptomania is a disorder in which the individual impulsively steals even though there is need to do so (i.e., the individual has money to pay for the stolen items or does not need the stolen goods). Like other ICDs, kleptomania is characterized by an anxiety-driven urge to perform an act that is pleasurable in the moment but causes significant distress and dysfunction [62]. The prevalence of kleptomania in the U.S. is unknown but has been estimated at 6 per 1000 people. [63] (Table 1). In addition, given the embarrassment surrounding kleptomania, it is often kept secret and thus goes undiagnosed [62]. Kleptomania is thought to account for 5% of shoplifting in the U.S. [64]. Based on total shoplifting costs of $10 billion in 2002 [65], this 5% translates into a $500 million annual loss to the economy attributable to kleptomania. This loss does not include the costs associated with stealing from friends and acquaintances or costs incurred by the legal system. Kleptomanic behavior carries serious legal consequences: approximately 2 million Americans are charged with shoplifting annually [66]. If kleptomania accounts for 5% of these, this translates into 100,000 arrests. Recent studies assessing the rate of OCD in patients with kleptomania have given widely differing estimates, ranging from 6.5% to 60% [67, 68] (Table 2).

C–I Internet usage disorder, also referred as Internet addiction or problematic Internet use, has been proposed as an explanation for uncontrollable and damaging use of the Internet, and has only recently begun to appear in the psychiatric literature [69, 70]. People with problematic Internet use often report increasing amounts of time-spent web surfing, gambling, shopping or exploring pornographic sites. Others report spending time in chat rooms or corresponding by email. Frequently these people develop a preoccupation with the Internet, a need for escape to the Internet and increasing irritability when trying to cut back their Internet use. Ultimately, their attempt to cut back is unsuccessful. Functional impairments as a result of problematic Internet use include marital or family strife, job loss or decreased job productivity, legal difficulties or school failure [72]. Although diagnostic criteria for this disorder have been proposed, methods of assessing C–I Internet usage disorder are limited. In addition, although increasing research is being conducted on the topic, several published articles contain information that has not been empirically researched [73]. For some individuals, their excessive Internet use may be entirely accounted for by another Axis I disorder such as PG or C–I sexual behaviors; thus the Internet is functioning simply as another outlet for that disorder rather than being an additional disorder. Problematic Internet use has been reported in any age, social, educational, and economic range [74]. However, while previous studies tended to stereotype the classical Internet addicted patient as a young introverted man [75, 76], recent investigations have showed increasing rates of this disorder among women [74], as a result of the increased availability of the Internet. The prevalence of C–I Internet usage disorder is not known. Most of the studies related to this condition have been conducted with small samples. People enrolled, moreover, frequently had comorbid psychiatric diagnoses. In a recent study [71], Shapira and colleagues found that all subjects with problematic Internet use also met DSM-IV criteria for ICD-NOS. Studies assessing comorbidity rates between OCD and C–I Internet use reported estimates ranging from 10% to 20% for lifetime OCD and up to 15% for current OCD in Internet addicted patients [71, 77, 78] (Table 2). Further investigations on the epidemiology of this disorder are needed to clarify the scale and demographic characteristics of C–I Internet use.

C–I sexual behaviors (C–ISBs) include repetitive sexual acts and compulsive sexual thoughts. The individual feels compelled or driven to perform the behavior, which may or may not cause subjective distress. Although generally not ego-dystonic, the behavior may interfere with several aspects of the patient’s life, causing social or occupational impairment, or legal and financial consequences [79]. C–ISBs involve a broad range of paraphilic or non-paraphilic symptoms [80]. Paraphilic C–ISBs involve unconventional sexual behaviors in which there is a disturbance in the object of sexual gratification or in the expression of sexual gratification (e.g., exhibitionism, voyeurism). Non-paraphilic C–ISBs, on the other hand, involve conventional sexual behaviors that have become excessive or uncontrolled [80]. The true prevalence of C–ISBs remains unknown, given the hetereogeneity of these disorders as well as the secretiveness of the condition for the majority of the afflicted patients. Investigations conducted in the early 1990s reported prevalence estimates of C–ISBs ranging from 5% to 6% of the US population [80, 81] (Table 1). Male patients have been traditionally reported to be more afflicted than women by C–ISBs [82, 83]. However, it is not clear how large this sex difference is and the extent to which the difference is due to men coming to the attention of professionals with greater frequency. Studies assessing the rates of OCD in patients suffering from C–ISBs [79, 84] reported estimates around 12% and 14% (Table 2).

C–I shopping, also referred as compulsive buying, is characterized by maladaptive preoccupations or impulses to buy or shop that are experienced as irresistible, intrusive and/or senseless, accompanied by frequent episodes of buying items that are not needed and/or that cost more than can be afforded. Frequently, these patients engage in these behaviors for longer periods of time than intended, and they experience distress and significant impairment in social and occupational performance. As specified for many other ICDs, the excessive buying or shopping behavior does not occur exclusively during periods of hypomania or mania [85, 86]. A recent study on C–I shopping disorder estimated the prevalence of this disorder to be between 2% and 8% of the general adult population in the US [87]; 80% to 95% of those affected are female (Table 1). Onset occurs in the late teens or early twenties, and the disorder is generally chronic. Previous studies investigating rates of OCD in patients with C–I shopping reported rates of 12.5% to 30% [86, 88] (Table 2); lower rates of compulsive buying have been found in patients with OCD (from 2.2% to 10.6%) [59, 60, 61], except for the study of Lejoyeux and colleagues (23.3%) [89].

Patients with C–I skin picking frequently present to dermatologists, and it has been estimated that about 2% of dermatology clinic patients may suffer from this condition [90, 91] (Table 1). Prevalence in the general population or in psychiatric clinics is unknown. Skin picking is often not a transient behavior but may persist with a waxing and waning lifetime course. It should be considered pathological when it becomes habitual, chronic and extensive, leading to significant distress, dysfunction or disfigurement [38]. As reported by two recent studies, the majority of patients with C–I skin picking are women and their condition is assumed to be chronic, with excoriations on both single or multiple sites [92, 93]; the face is the most common site of excoriation but picking can involve any area of the body. Both studies found the majority of patients experienced increasing tension before the act (79–81%), relief after the act (52–79%), or both (68–90%). Comorbid lifetime rates of skin picking in patients with trichotillomania were approximately 10% in both studies [92, 93], whereas comorbid lifetime OCD was present in rates ranging from 6% to 19%. Wilhelm and colleagues [94] reported rates of OCD around 52% in a sample of 31 patients with C–I skin picking (Table 2). As mentioned for trichotillomania, the inclusion of C–I skin picking within a spectrum of self-injurious behaviors is receiving increasing support from clinical and neuroimaging studies [38].

Treatment options for ICDs

Treatment options for ICDs include both pharmacotherapy and psychotherapy. During the last decade, increasing research has been conducted on different pharmacological treatments across several ICDs; however, while the efficacy of various treatments has been investigated in double-blind studies for certain disorders (i.e., PG, IED, C–I shopping), systematic research of clinical treatment is still lacking for other disorders (see Table 3). In addition, a crucial issue to take into account when considering pharmacotherapy for patients with ICDs is the comorbidity with other psychiatric conditions such as affective and addictive disorders. The presence of bipolar or addictive comorbidity, in fact, will determine the most appropriate choice when different treatments have proven to be effective for a specific disorder.
Table 3

Treatment options for impulse control disorders as reported in blinded and unblinded studies

Impulse Control Disorder

Double-blind studies (references)


Other treatment options as reported in open-label trials

Pathological Gambling

Fluvoxamine vs. PC (Hollander et al. 2000; Blanco et al. 2002)

SSD for Fluvoxamine; No SSD between Fluvoxamine and PC.

Nefazodone, Bupropion, Citalopram, Divalproex, Topiramate

Paroxetine vs. PC (Kim et al. 2002; Potenza et al. 2003)

SSD for Paroxetine; No SSD between Paroxetine and PC.

Lithium vs. PC (Hollander et al. 2005)

SSD for Lithium;

Naltrexone vs. PC (Kim et al. 2001)

SSD for Naltrexone


Clomipramine vs. Desipramine (Swedo et al. 1989)

SSD for Clomipramine;

Fluvoxamine, Citalopram, Venlafaxine, Naltrexone, Lithium, CBT

Fluoxetine vs. PC (Christenson et al. 1991; Streichenvein and Thornby 1995)

No SSD between Fluoxetine and PC


CBT and other psychotherapies

Intermittent Explosive Disorder

*Lithium vs. PC (Campbell et al. 1984 and 1995; Malone et al. 1998 and 2000)

SSD for Lithium (in the Campbell’ study of 1984, Lithium was associated to Haloperidol)


*Divalproex vs. PC (Hollander et al. 2003 and 2005)

SSD for Divalproex

*Fluoxetine vs. PC (Coccaro et al. 1997)

SSD for Fluoxetine

*Carbamazepine vs. PC (Foster et al. 1989)

SSD for Carbamazepine

*Phenytoin vs. PC (Barratt et al. 1997; Stanford et al. 2001)

SSD for Phenytoin

*BBlockers vs. PC (Greendyke et al. 1986a and 1986b)

SSD for BBlockers

*Risperidone vs. PC (Buitelaar et al. 2001; Findling et al. 2001)

SS for Risperidone

*CBT vs. PC (Alpert et al. 1997)



Fluoxetine, Paroxetine, Fluvoxamine, Divalproex, Lithium, Benzodiazepines

C–I Internet Usage Disorder

Escitalopram vs. PC (Dell’Osso et al. 2006**)

SSD for Escitalopram


C–I Shopping

Fluvoxamine vs. PC (Black et al. 2000; Ninan et al. 2000)

No SSD between Fluvoxamine and PC;

Fluvoxamine, Naltrexone

Citalopram vs. PC (Koran et al. 2003)

SSD for Citalopram

C–I Skin Picking

Fluoxetine vs. PC (Simeon et al. 1997; Block et al. 2000)

SSD for Fluoxetine

Clomipramine, Sertraline

C–I Sexual Behaviors

Lithium, Tricyclics, Buspirone, Fluoxetine, Nefazodone, Sertraline, Naltrexone

SSD = statistically significant differences; CBT = cognitive behavioral therapy; PC = placebo

* Studies on patients with impulsive aggression features, rather than with a proper DSM diagnosis of IED

** Open-label study followed by double-blind discontinuation phase (Abstract)

PG is a good example of the importance of comorbidity determining treatment. PG has demonstrated a good response to selective serotonin reuptake inhibitors (SSRIs), mood stabilizers and opioid antagonists in double-blind studies [22, 95, 96, 97, 98, 99] (Table 3). Among all the antidepressants assessed so far, fluvoxamine [100], paroxetine [97, 98], citalopram [101], nefazodone [102], bupropion [103], (although only fluvoxamine and paroxetine in double-blind studies), the most convincing evidence is for the efficacy of the SSRIs. However, a major issue for this class of medication is the presence of bipolar spectrum comorbidity in some gamblers. This possibility needs to be carefully evaluated and excluded before treating pathological gamblers with antidepressants in order to avoid the possible reemergence of manic symptoms. The opioid antagonist naltrexone was effective in a double-blind trial, however, the risk of hepatotoxicity of this drug limits its use. Of note, the opioid antagonist nalmefene has shown to be efficacious in preliminary findings with better tolerability than naltrexone [104]. Patients with other addictive disorders (alcohol and other substances) and intense urges and craving might particularly benefit from opioid antagonists. Mood stabilizers and anticonvulsants (lithium and divalproex assessed in double-blind controlled trials) have shown good results in recent studies without any specific contraindications for their use across the different subtypes of gamblers. In addition, gamblers with consistent affective instability may particularly benefit from these treatments.

Pharmacological treatment of TTM is not well established and, although SSRIs seem to show the best efficacy and safety, double-blind controlled studies on their use have given mixed results (Table 3). Clomipramine was found to be more effective than desipramine in a 10-week crossover study [105] conducted in the late 1980s. While subsequent uncontrolled studies found fluoxetine, fluvoxamine and citalopram to be efficacious in patients with hair pulling [106, 107, 108, 109, 110], two controlled studies [111, 112] with fluoxetine could not replicate the positive findings reported with SSRIs in the open-label trials. Positive results have been also reported in uncontrolled studies with venlafaxine, lithium and naltrexone [113, 114, 115, 116] as well as in open-label augmentation studies with SSRIs and pimozide [117, 118]. However, treatment response is often disrupted by significant relapse during ongoing pharmacological treatment [117]. In a recent controlled study [119] comparing cognitive behavioral therapy (CBT) to clomipramine and placebo, CBT had a dramatic effect in reducing symptoms of TTM and was significantly more effective than clomipramine or placebo, underscoring the efficacy of behavioral as well as pharmacological treatment in hair pulling.

To our knowledge, no controlled pharmacological trial has been conducted in patients with pyromania. Non-pharmacological interventions for firesetters, including CBT [120], short-term counseling and day-treatment programs [121], have shown some efficacy. Undoubtedly, pyromania represents an ICD needing systematic pharmacotherapy research.

Treatment options for IED include the use of mood stabilizers, phenytoin, SSRIs, β-blockers, α2-agonists and antipsychotics (Table 3). Actually the majority of trials with these compounds have been conducted on individuals with impulsive aggression rather than with a specific diagnosis of IED, and several authors still don’t consider the current criteria for the diagnosis of IED to be adequate [122]. Nevertheless, the presence of impulsive aggression within the core features of IED allows us to put aside this nosographic debate. Among mood stabilizers, the most convincing evidence comes from controlled studies with lithium (especially in children and adolescents) [123, 124, 125, 126, 127] and divalproex [128]. This last medication demonstrated significant efficacy in different populations of aggressive subjects [129, 130]. Carbamazepine has also shown some efficacy in a small double-blind study and in open-label trials [131, 132]. Phenytoin has showed positive results in two controlled double-blind studies [133, 134] at doses up to 300 mg/d. With regard to SSRIs, a double-blind placebo controlled trial of fluoxetine [135] in patients with personality disorder showed reduced scores on measures of irritability and aggression in patients taking the active medication. B-blockers propranolol and pindolol have also shown positive results in controlled studies [136, 137], reducing aggressive behaviors in patients with brain damage, although their concomitant diagnosis of IED might be arguable as the aggressive behaviors may have a different etiology. The α-agonist clonidine was reported to decrease aggression in an open-label trial [138] with adolescents at dosages of 0.4 mg/d, although the tolerability was a problem for some subjects. The atypical antipsychotic risperidone was also showed to be effective in treating aggression in controlled studies [139, 140]. Finally, controlled studies of behavioral interventions including CBT, group therapy, family therapy and social skill training have shown them to be valid treatments for aggressive patients [141, 142].

The pharmacological treatment of kleptomania includes SSRIs, mood stabilizers and opioid antagonists, although none of these medications have been tested in blinded, controlled trials so far (Table 3). Among SSRIs, fluoxetine, alone or in combination with lithium or tricyclics, was shown to be effective in several case-reports [64, 143, 144], as were fluvoxamine and paroxetine [145, 146, 147, 148]. Mood stabilizer trials and reports in kleptomanic patients showed mixed results for lithium [64, 144, 145], valproic acid [64, 149] and carbamazepine [64]. The opioid antagonist naltrexone was reported to be effective in two different case reports [148, 150]. Finally the benzodiazepines clonazepam and alprazolam provided some evidence of efficacy in treating kleptomania [64, 147]. In conclusion, as discussed in a recent review [151], SSRIs seem to be the most promising treatment for kleptomania (19 of 30 cases of successful pharmacotherapy reported in the literature), either as monotherapy or in combination with other psychotropic drugs.

Given its recent recognition as a psychiatric problem, understandably no controlled pharmacological trials have been published on the treatment of C–I Internet usage disorder so far. Recently, Sattar and Ramaswamy [152] reported the case of a 31-year-old man with severe Internet addiction successfully treated with escitalopram (10 mg/d). Most treatment strategies for problematic Internet use have involved behavioral therapy techniques, which limit the amount of time on the Internet rather than requiring abstinence, as is done with many other addictions such as substance abuse. Self-help groups (both on and offline) are also being formed to address the problem. Our group has recently completed an open-label trial of escitalopram followed by a double-blind discontinuation phase in a population of C–I Internet users with preliminary positive findings [153]. Given the increasing use of the Internet in the new generations, a growing prevalence and incidence of this disorder is arguable. Clinicians treating subjects with ICDs should always assess the presence of this disorder in these patients given the relationship between C–I Internet use and some specific ICDs, such as pathological gambling and C–I sexual behaviors [154, 155]. Finally, controlled studies are expected in order to investigate the treatment response of Internet addicted patients to pharmacotherapy and psychotherapy.

Although C–I sexual behaviors seem relatively common, controlled trials on pharmacological treatments for these disorders are still lacking, and the available literature on this topic consists essentially of open-label trials and case-report series (Table 3). Positive findings have been reported with lithium and tricyclics [156, 157, 158], SRIs [159, 160, 161, 162], buspirone [163, 164] and nefazodone [165]. As for other ICDs, the opioid antagonist naltrexone has recently shown to be efficacious in some case-reports [166]. Finally, different forms of psychotherapy have been shown to be effective for specific subtypes of C–I sexual behaviors [167].

There is some evidence that C–I shopping has been effectively treated with several different compounds (Table 3). McElroy’s group [86] reported on 20 patients that benefited from antidepressants, often in combination with mood stabilizers. Black [168] reported fluvoxamine to be effective in patients without comorbid major depression, suggesting that improvement was independent of the treatment of mood symptoms. Naltrexone was found to be effective in a case series [169]. Two double-blind placebo-controlled trials [170, 171] did not confirm the superiority of fluvoxamine over placebo. However, these studies had the patients in both conditions keep a log of their shopping; keeping logs is a therapeutic intervention in itself and may have led to the failure of the fluvoxamine and placebo groups to separate. An open-label trial of citalopram [172] and a subsequent open-label trial followed by double-blind discontinuation [173], neither of which using shopping logs, reported positive results. Studies comparing the efficacy of pharmacological treatment with psychotherapy have not been published yet.

Patients suffering from C–I skin picking often meet criteria for other psychiatric disorders (BDD and OCD), and frequently, due to medical complications of their psychopathology such as infection and scarring, they are referred to clinicians other than psychiatrists (i.e. dermatologists). The first controlled trial conducted by our group [97] found fluoxetine, at a mean dose of 55 mg/d for 10 weeks, significantly superior to placebo in decreasing the behavior in 21 adults with chronic pathologic skin picking (Table 3). More recently, a combined open-label and double-blind trial [174] confirmed the efficacy of fluoxetine in subjects with C–I skin picking. Previously, a retrospective treatment review of BDD patients with skin picking indicated that SRIs were effective in about half of 33 patients, whereas other agents were not [175]. In a subsequent open-label study [176], sertraline (mean dose: 95 mg/d) showed clinically significant improvement in 68% of 30 patients with skin picking after one month of treatment. Finally, uncontrolled psychodynamically oriented treatments and behavioral interventions have given mixed results described elsewhere [177].


Current knowledge on ICDs in terms of epidemiology and pharmacological treatment varies notably across these disorders, with recent and continuing advances for some (i.e. pathological gambling and C–I shopping), and anecdotal and obsolete data for others. Undoubtedly, given the high prevalence estimates of some ICDs (i.e. pathological gambling and C–I sexual behaviors) as well as their comorbidity with other major psychiatric disorders, this group of disorders represents a global problem. Nevertheless, certain ICDs (i.e, pyromania, C–I Internet usage disorder) still need systematic epidemiological and pharmacological research.

Studying the relationships between specific ICDs and other major psychiatric conditions (i.e. OCD, bipolar disorders, addictive disorders) in terms of phenomenological issues and comorbidity patterns is not only of theoretical interest; indeed, it provides the rationale for the use of specific pharmacological treatments and behavioral interventions. From this perspective, more than one decade after its introduction, the conceptualization of ICDs as obsessive–compulsive related disorders is still valid and has been confirmed by numerous studies; however, there is also evidence supporting the relationship between ICDs and addictive and affective disorders. Not only are the different models of conceptualizing the ICDs not mutually exclusive, but they can contribute to recognize specific subtypes within the disorders. As a result, different models of conceptualization of ICDs have led new developments in pharmacologic treatment of these disorders, with positive results obtained with mood stabilizers and opioid antagonists in addition to the SSRIs.


  1. 1.
    Hollander E (1993) In: Hollander E (ed) Obsessive–Compulsive Related Disorders, American Psychiatric Publishing, Inc, Washington, DC, pp 1–16Google Scholar
  2. 2.
    Hollander E, Stein DJ, DeCaria CM, et al. (1992) Disorders related to OCD—neurobiology. Clin Neuropharmacol 15(S1)Pt A:259A–260APubMedGoogle Scholar
  3. 3.
    McElroy SL, Phillips KA, Keck PE Jr (1994) Obsessive compulsive spectrum disorder. J Clin Psychiatry 55(Suppl):33–51;discussion 52–3PubMedGoogle Scholar
  4. 4.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. text revision. American Psychiatric Association, Washington, DCCrossRefGoogle Scholar
  5. 5.
    Asahi S, Okamoto Y, Okada G, et al. (2004) Negative Correlation between right prefrontal activity during response inhibition and impulsiveness: a fMRI study. Eur Arch Psychiatry Clin Neurosci 254(4):245–251PubMedGoogle Scholar
  6. 6.
    Rufer M, Fricke S, Held D, et al. (2006) Dissociation and symptom dimensions of obsessive compulsive disorder: a replication study. Eur Arch Psychiatry Clin Neurosci 256(3):146–150PubMedCrossRefGoogle Scholar
  7. 7.
    Gerstein D, Volberg RA, Harwood H, et al. (1999) Gambling impact and behavior study. Report to the National Gambling Impact Study Commission. National Opinion Research Center at the University of Chicago, ChicagoGoogle Scholar
  8. 8.
    Welte J, Barnes G, Wieczorek Q, et al. (2001) Alcohol and gambling pathology among U.S. adults: prevalence, demographic patterns and comorbidity. J Studies Alcohol 62:706–712Google Scholar
  9. 9.
    Shaffer H, Hall M, Vander Bilt J (1997) Estimating the prevalence of disordered gambling behavior in the United States and Canada. A meta-analysis. Presidents and Fellows of Harvard College, BostonGoogle Scholar
  10. 10.
    Abbott MW, Volberg RA (2000) Taking the pulse on gambling and problem gambling in New Zealand. A report on Phase One of the 1999. National Prevalence Survey. Department of International Affairs, WellingtonGoogle Scholar
  11. 11.
    Abbott MW (2001) Problem and non problem Gamblers in New Zealand: a report on Phase II of the 1999 National Prevalence Survey. Report Number 6 of the New Zealand Gambling Survey. Department of International Affairs, WellingtonGoogle Scholar
  12. 12.
    Abbott MW (2001) What do we know about gambling and problem gambling in New Zealand: a report on Phase II of the 1999 National Prevalence Survey. Report Number 7 of the New Zealand Gambling Survey. Department of International Affairs, WellingtonGoogle Scholar
  13. 13.
    Ronnberg S, Volberg RA, Abbott MW, et al. (1999) Gambling and problem gambling in Sweden. Report Number 2 of the National Institute of Public Health Series on Gambling. National Institute of Public Health, StockholmGoogle Scholar
  14. 14.
    Volberg RA, Abbott MW, Ronnberg S, et al. (2001) Prevalence and risks of pathological gambling in Sweden. Acta Psych Scand 104:250–256CrossRefGoogle Scholar
  15. 15.
    Bondolfi G, Osiek C, Ferrero F (2000) Prevalence estimates of pathological gambling in Switzerland. Acta Psych Scand 101:473–475CrossRefGoogle Scholar
  16. 16.
    Productivity Commission: Australia’s gambling industries. Report No. 10. Canberra. AusInfoGoogle Scholar
  17. 17.
    Sproston K, Erens R, Oxford J (2000) Gambling behavior in Britain. Results from the British gambling prevalence survey. National Centre for Social Research, LondonGoogle Scholar
  18. 18.
    Roy A, Adinoff B, Roehrich L, et al. (1988) Depressed pathological gamblers. Acta Psychiatr Scand 77:163–165PubMedCrossRefGoogle Scholar
  19. 19.
    National Research Council (1999) Pathological gambling: a critical review. National Academy Press, Washington, DCGoogle Scholar
  20. 20.
    Linden RD, Pope HG, Jonas JM (1986) Pathological gambling and major affective disorders: preliminary findings. J Clin Psychiatry 47:201–203PubMedGoogle Scholar
  21. 21.
    Potenza MN, Fiellin DA, Hieninger GR, et al. (2002) Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med 17(9):721–732PubMedCrossRefGoogle Scholar
  22. 22.
    Hollander E, Pallanti S, Allen A, et al. (2005) Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 162(1):137–145PubMedCrossRefGoogle Scholar
  23. 23.
    Dell’Osso B, Allen A, Hollander E (2005) Comorbidity issues in the pharmacological treatment of pathological gambling: a critical review. Clin Pract Epidemol Ment Health Oct 10;1(1):21Google Scholar
  24. 24.
    Hantouche E, Merckaert P (1991) Nosological classifications of obsessive–compulsive disorder. Ann Med Psychol 149:393–408Google Scholar
  25. 25.
    Hollander E, Skodol A, Oldham J (1996) Impulsivity and compulsivity. American Psychiatric Press, Washington, DCGoogle Scholar
  26. 26.
    Cartwright C, DeCaria C, Hollander E (1998) Pathological gambling: a clinical review. Practical Psychiatry and Behavioral Health 4:277–286Google Scholar
  27. 27.
    Lesieur HR (1979) The compulsive gambler’s spiral of options and involvement. Psychiatry 42:79–87PubMedGoogle Scholar
  28. 28.
    Leisieur HR, Custer RL (1984) Pathological gambling: roots, phases and treatment. Ann Acad Poll Soc Sci 474:146–156CrossRefGoogle Scholar
  29. 29.
    Rasmussen SA, Eisen JL (1992) The epidemiology and differential diagnosis of obsessive–compulsive disorder. J Clin Psychiatry 53:4–10PubMedGoogle Scholar
  30. 30.
    Argo TR, Black DW (2004) Clinical characteristics. In: Grant JE, Potenza MN (eds) Pathological Gambling: A Clinical Guide to Treatment. American Psychiatric Publishing, Inc, Washington, DC, pp 39–53Google Scholar
  31. 31.
    Swedo E, Rapoport JL (1991) Annotation: trichotillomania. J Child Psychol Psychiatry 32:401–409PubMedCrossRefGoogle Scholar
  32. 32.
    Christenson GA, Pyle RL, Mitchell JE (1991) Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry 52:415–417PubMedGoogle Scholar
  33. 33.
    Stanley MA, Borden JW, Bell GE, et al. (1994) Nonclinical hair-pulling phenomenology and related psychopathology. J Anxiety Disord 8:119–130CrossRefGoogle Scholar
  34. 34.
    Swedo SE, Trichotillomania (1993) In: Hollander E (ed) Obsessive–compulsive related disorders, American Psychiatric Publishing, Inc, Washington, DC, pp 93–113 and 256Google Scholar
  35. 35.
    Lenane MC, Swedo SE, Rapoport JL, et al. (1992) Rates of Obsessive Compulsive Disorder in first degree relatives of patients with trichotillomania: a research note. J Child Psychol Psychiatry 33(5):925–33PubMedCrossRefGoogle Scholar
  36. 36.
    Stein DJ, Simeon D, Cohen LJ, et al. (1995) Trichotillomania and obsessive–compulsive disorder. J Clin Psychiatry 56(S4):28–34PubMedGoogle Scholar
  37. 37.
    Christenson GA, Mansueto CS (1999) descriptive characteristics and phenomenology. In: Stein DJ, Christenson GA, Hollander E (eds) Trichotillomania. American Psychiatric Publishing, Inc, Washington, DC, pp 1–42Google Scholar
  38. 38.
    Simeon D, Favazza AR (1995) Self-injurious behaviors, phenomenology and assessment. In: Simeon D, Hollander E (eds) Self-injurious behaviors, assessment and treatment. American Psychiatric Publishing, Inc, Washington, DC, pp 1–28Google Scholar
  39. 39.
    Lochner C, Seedat S, du Toit PL, et al. (2005) Obsessive–compulsive disorder and trichotillomania: a phenomenological comparison. BMC Psychiatry 5:2PubMedCrossRefGoogle Scholar
  40. 40.
    Jacobson RR (1985) Child firesetters. a clinical investigation. J Child Psychol Psychiatry 26:759PubMedCrossRefGoogle Scholar
  41. 41.
    Kosky RJ, Silburn S (1984) Children who light fires: a comparison between firesetters and non-firesetters referred to a child psychiatrist outpatient service. Aust N Z J Psychiatry 18:251–255PubMedCrossRefGoogle Scholar
  42. 42.
    Kolko DJ, Kadzin AE (1988) Prevalence of firesetting and related behaviors among child psychiatric patients. J Consult Clin Psychol 56:628–630PubMedCrossRefGoogle Scholar
  43. 43.
    Barnett W, Spitzer R (1994) Pathological firesetting 1951–1991: a review. Med Sci Law 34:4–20PubMedGoogle Scholar
  44. 44.
    Strachan JG (1981) Conspicuous firesetting in children. Br J Psychiatry 138:26–29PubMedCrossRefGoogle Scholar
  45. 45.
    Jones RT, Langley AK, Penn C (2001) Firesetting. In: Orvaschel H, Faust J (eds) Handbook of conceptualization and treatment of child psychopathology. Pergamon/Elsevier, Amsterdam, pp 355–378CrossRefGoogle Scholar
  46. 46.
    Raines JC, Foy CW (1994) Extinguishing the fires within: treating juvenile firesetters. Fam Soc-J Contemp H 75:595–606Google Scholar
  47. 47.
    Soltys SM (1992) Pyromania and firesetting behaviors. Psychiatr Ann 22:79–83Google Scholar
  48. 48.
    Jesor R, Jesor SL (1977) Problem behavior and psychosocial development. Academic Press, New YorkGoogle Scholar
  49. 49.
    Stickle TR, Blechman EA (2002) Aggression and fire: antisocial behavior in firesetting and nonfiresetting juvenile offenders. J Psychopathol Behav Assess 24:177–193CrossRefGoogle Scholar
  50. 50.
    Geller JL (1987) Firesetting in the adult psychiatric populations. Hosp Commun Psychiatry 38:501–506Google Scholar
  51. 51.
    Chen YH, Arria AM, Anthony JC (2003) Firesetting in adolescence, and being aggressive, shy, and rejected by peers: New epidemiologic evidence from a national sample survey. J Am Acad Psychiatry Law 31:44–52PubMedGoogle Scholar
  52. 52.
    Monopolis S, Lion JR (1983) Problems in the diagnosis of intermittent explosive disorder. Am J Psychiatry 140:1200–1202PubMedGoogle Scholar
  53. 53.
    Felthous AR, Bryant G, Wingerter CBV, et al. (1991) The diagnosis of intermittent explosive disorder in violent men. Bull Am Acad Psychiatry Law 19:71–79PubMedGoogle Scholar
  54. 54.
    Coccaro EF, Schmidt CA, Samuels JF, et al. (2004) Lifetime and 1-Month Prevalence Rates of Intermittent Explosive Disorder in a Community Sample. J Clin Psychiatry 65:820–824PubMedCrossRefGoogle Scholar
  55. 55.
    American Psychiatric Association (1980) Diagnostic and statistical manual of mental disorders, 3rd edn, text revision. Washington, DC, American Psychiatric AssociationGoogle Scholar
  56. 56.
    Coccaro EF, Kavoussi RJ, Berman RE, et al. (1998) Intermittent explosive disorder-revised: development, reliability and validity of research criteria. Compr Psychiatry 39:368–376PubMedCrossRefGoogle Scholar
  57. 57.
    Coccaro EF (2003) Intermittent explosive disorder. In: Coccaro EF (eds) Aggression, psychiatric treatment and assessment. Marcel Dekker, New York, NY, pp 149–166CrossRefGoogle Scholar
  58. 58.
    McElroy SL, Soutullo CA, Beckman DA, et al. (1998) DSM-IV intermittent explosive disorder: a report of 27 cases. J Clin Psychiatry 59:203–210PubMedGoogle Scholar
  59. 59.
    du Toit PL, van Kradenburg J, Niehaus D, et al. (2005) Comparison of obsessive–compulsive disorder in patients with and without comorbid putative obsessive compulsive spectrum disorders using a structured clinical interview. Compr Psychiatry 42:291–300CrossRefGoogle Scholar
  60. 60.
    Fontenelle LF, Mendlowicz MV, Versiani M, et al. (2005) Impulse control disorders in patients with obsessive–compulsive disorder. Psychiatry Clin Neurosci 59:30–37PubMedCrossRefGoogle Scholar
  61. 61.
    Matsunaga H, Kiriike N, Matsui T, et al. (2005) Impulsive disorders in Japanese adult patients with obsessive–compulsive disorder. Compr Psychiatry 46:105–110CrossRefGoogle Scholar
  62. 62.
    Aboujaoude E, Gamel N, Koran LM (2004) Overview of Kleptomania and Phenomenological Description of 40 Patients. Prim Care Companion J Clin Psychiatry 6:244–247PubMedCrossRefGoogle Scholar
  63. 63.
    Goldman MJ (1991) Kleptomania: making sense of the nonsensical. Am J Psychiatry 148:986–996PubMedGoogle Scholar
  64. 64.
    McElroy SL, Pope HG, Hudson JL, et al. (1991) Kleptomania: a report of 20 cases. Am J Psychiatry 148:652–657PubMedGoogle Scholar
  65. 65.
    Hollinger RC, Davis JL (2003) 2002 National retail security survey final report. University of Florida, Gainesville FlaGoogle Scholar
  66. 66.
    Goldman MJ (1998) Kleptomania. The compulsion to steal- what can be done? New Horizon Press, Far Hills, NJGoogle Scholar
  67. 67.
    Grant JE, Kim SW (2002) Clinical characteristics and associated psychopathology of 22 patients with kleptomania. Compr Psychiatry 43:378–384PubMedCrossRefGoogle Scholar
  68. 68.
    Presta S, Marazziti D, Dell’Osso L, et al. (2002) Kleptomania: clinical features and comorbidity in an Italian sample. Compr Psychiatry 43:7–12PubMedCrossRefGoogle Scholar
  69. 69.
    Grant JE (2003) Family History and Psychiatric Comorbidity in Persons with Kleptomania. Compr Psychiatry 44:437–441PubMedCrossRefGoogle Scholar
  70. 70.
    Stein DJ (1997) Internet addiction, internet psychotherapy [letter; comment]. Am J Psychiatry 153:890Google Scholar
  71. 71.
    Shapira NA, Goldsmith TD, Keck PA, et al. (2000) Psychiatric features of individuals with problematic Internet use. J Affect Disord 57:(issues 1–3):267–272PubMedCrossRefGoogle Scholar
  72. 72.
    Beard KW (2005) Internet addiction: a review of current assessment techniques and potential assessment questions. Cyberpsychol Behav 8:7–14PubMedCrossRefGoogle Scholar
  73. 73.
    Cho C, Hsiao MC (2000) Internet Addiction, usage, gratification, and pleasure experience: the Taiwan college students’ case. Comput Educ 35:65–80CrossRefGoogle Scholar
  74. 74.
    Young KS (1998) Caught in the net. John Wiley & Sons, New YorkGoogle Scholar
  75. 75.
    Scherer K (1997) College-life online: healthy and unhealthy Internet use. J Coll Student Dev 38:655–665Google Scholar
  76. 76.
    Young KS (1996) Psychology of computer use: XL. Addictive use of the internet: a case that breaks the stereotype. Psychol Rep 79:899–902PubMedGoogle Scholar
  77. 77.
    Black DW, Belsare G, Schlosser S (1999) Clinical Features, psychiatric comorbidity, and health-related quality of life in persons reporting compulsive computer use behavior. J Clin Psychiatry 60:839–844PubMedGoogle Scholar
  78. 78.
    Shapira NA, Lessig MC, Goldsmith TD, et al. (2003) Problematic internet use: proposed classification and diagnostic criteria. Dep Anxiety 17:207–216CrossRefGoogle Scholar
  79. 79.
    Black DW, Kehrberg LLD, Flumerfelt DL, et al. (1997) Characteristics of 36 subjects reporting compulsive sexual behavior. Am J Psychiatry 154:243–249PubMedGoogle Scholar
  80. 80.
    Coleman E (1991) Compulsive sexual behavior. New concepts and treatments. J Psychol Hum Sexual 4:37–52CrossRefGoogle Scholar
  81. 81.
    Schaffer SD, Zimmerman ML (1990) The sexual addict: a challenge for the primary care provider. Nurse Pract 15:25–33PubMedCrossRefGoogle Scholar
  82. 82.
    Cooper AJ, Swaminath S, Baxter D, et al. (1990) A female sex offender with multiple paraphilias: a psychologic, physiologic (laboratory sexual arousal) and endocrine case study. Can J Psychiatry 35:334–337PubMedGoogle Scholar
  83. 83.
    Weissberg JH, Levay AN (1986) Compulsive sexual behavior. Medical Aspects Human Sexuality 20:129–132Google Scholar
  84. 84.
    Kafka MP, Prentky R (1994) Preliminary observations of DSM-III-R Axis I comorbidity in men with paraphilias and paraphilia-related disorders. J Clin Psychiatry 55:481–487PubMedGoogle Scholar
  85. 85.
    McElroy SL, Keck Jr PE, Phillips KA. (1995) Kleptomania, compulsive buying and binge-eating disorder. J Clin Psychiatry 56(S4):14–26PubMedGoogle Scholar
  86. 86.
    McElroy SL, Keck PE Jr, Pope HG Jr, et al. (1995) Compulsive buying: a report of 20 cases. J Clin Psychiatry 55–56:242–248Google Scholar
  87. 87.
    Black DW (2001) Compulsive buying disorder: definition, assessment, epidemiology and clinical management. CNS Drugs 15(1):17–27PubMedCrossRefGoogle Scholar
  88. 88.
    Christenson GA, Faber RJ, de Zwaan M, et al. (1994) Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 55:5–11PubMedGoogle Scholar
  89. 89.
    Lejoyeux M, Bailly F, Moula H, et al. (2005) Study of compulsive buying in patients presenting obsessive–compulsive disorder. Compr Psychiatry 46:105–110PubMedCrossRefGoogle Scholar
  90. 90.
    Doran AR, Roy A, Wolkowitz OM (1985) Self destructive dermatoses. Psychiat Clin N Am 8:291–298Google Scholar
  91. 91.
    Gupta MA, Gupta AK, Haberman HR (1986) Neurotic excoriations: a review and some new perspectives. Compr Psychiatry 27:381–386PubMedCrossRefGoogle Scholar
  92. 92.
    Simeon D, Stein DJ, Gross S, et al. (1997) A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry 58:341–347PubMedGoogle Scholar
  93. 93.
    Arnold LM, McElroy SL, Mutasim DF, et al. (1998) Characteristics of 34 adults with psychogenic excoriation. J Clin Psychiatry 59:509–514PubMedGoogle Scholar
  94. 94.
    Wilhelm S, Keuthen NJ, Deckersbach T, et al. (1999) Self-injurious skin picking: clinical characteristics and comorbidity. J Clin Psychiatry 60:454–459PubMedGoogle Scholar
  95. 95.
    Blanco C, Petkova E, Ibanez A, et al. (2002) A Pilot Placebo-Controlled Study of Fluvoxamine for Pathological Gambling. Ann Clin Psychiatry 14:9–15PubMedGoogle Scholar
  96. 96.
    Hollander E, DeCaria CM, Finkekk JN, et al. (2000) A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry 47(9):813–817PubMedCrossRefGoogle Scholar
  97. 97.
    Kim SW, Grant JE, Adson DE, et al. (2002) A Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Paroxetine in the treatment of Pathological Gambling. J Clin Psychiatry 63:501–507PubMedGoogle Scholar
  98. 98.
    Grant JE, Kim SW, Potenza MN, et al. (2003) Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol 18:243–249PubMedCrossRefGoogle Scholar
  99. 99.
    Kim SW, Grant JE, Adson DE, et al. (2001) Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49(11):914–921PubMedCrossRefGoogle Scholar
  100. 100.
    Hollander E, DeCaria CM, Mari E, et al. (1998) Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry 155(12):1781–1783PubMedGoogle Scholar
  101. 101.
    Zimmerman M, Breen RB, Posternak MA (2002) An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 63(1):44–48PubMedGoogle Scholar
  102. 102.
    Pallanti S, Baldini-Rossi N, Sood E, et al. (2002) Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry 63(11):1034–1039PubMedGoogle Scholar
  103. 103.
    Black DW (2004) An open-label trial of bupropion in the treatment of pathologic gambling. J Clin Psychopharmacol 24(1):108–110PubMedCrossRefGoogle Scholar
  104. 104.
    Grant John (2005) A multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling. Presented at the 45th NCDEU Meeting, Boca Raton, Florida, June 6–9Google Scholar
  105. 105.
    Swedo SE, Leonard HL, Rapoport JL, et al. (1989) A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 321:497–501PubMedCrossRefGoogle Scholar
  106. 106.
    Stanley MA, Bowers TC, Swann AC, et al. (1991) Treatment of trichotillomania with fluoxetine. J Clin Psychiatry 52:282PubMedGoogle Scholar
  107. 107.
    Koran LM, Ringold A, Hewlett W (1992) Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacol Bull 28:145–149PubMedGoogle Scholar
  108. 108.
    Winchel RM, Jones JS, Stanley B, et al. (1992) Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry 53:304–308PubMedGoogle Scholar
  109. 109.
    Stein DJ, Bouwer C, Maud CM (1997) Use of the selective serotonin reuptake inhibitor citalopram in the treatment of trichotillomania. Eur Arch Psy Clin N 247:234–236CrossRefGoogle Scholar
  110. 110.
    Christenson GA, Crow SG, Mitchell JE, et al. (1998) Fluvoxamine in the treatment of trichotillomania: an 8-week, open-label study. CNS Spectrums 3:64–71Google Scholar
  111. 111.
    Christenson GA, Mackenzie TB, Mitchell JE, et al. (1991) A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 148:1566–1571PubMedGoogle Scholar
  112. 112.
    Streichenwein SM, Thornby JI (1995) A long-term, double-blind, placebo-controlled, crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry 152:1192–1196PubMedGoogle Scholar
  113. 113.
    O’Sullivan RL, Keuthen NJ, Rodriguez D, et al. (1998) Venlafaxine treatment of trichotillomania: an open case series of ten cases. CNS Spectrums 3:56–63Google Scholar
  114. 114.
    Ninan PT, Knight B, Kirk L, et al. (1998) A controlled trial of venlafaxine in trichotillomania: interim phase I results. Psychopharmacol Bull 34(2):221–224PubMedGoogle Scholar
  115. 115.
    Christenson GA, Mackenzie TB, Mitchell JE, et al. (1991) Lithium treatment of chronic hair pulling. J Clin Psychiatry 52:116–120PubMedGoogle Scholar
  116. 116.
    Christenson GA, Crow JC, Mackenzie TB, et al. (1995) A placebo-controlled double-blind study of naltrexone for trichotillomania. Presented at the Annual Meeting of the American Psychiatric Association, Miami, Florida, MayGoogle Scholar
  117. 117.
    Stein DJ, Hollander E (1992) Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 53:123–126PubMedGoogle Scholar
  118. 118.
    van Ameringen M, Mancini C (1996) Treatment of trichotillomania with haloperidol. Anxiety Disorders Association of America Annual Meeting. Orlando, FLGoogle Scholar
  119. 119.
    Ninan PT, Rothbaum BO, Marsteller FA, et al. (2000) A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J Clin Psychiatry 61(1):47–50PubMedGoogle Scholar
  120. 120.
    Kolko DJ (2001) Efficacy of cognitive-behavioral treatment and fire safety education for children who set fires: initial and follow-up outcomes. J Child Psychol Psychiatry 42(3):359–369PubMedCrossRefGoogle Scholar
  121. 121.
    Slavkin ML (2002) Child & Adolescent Psychiatry: What Every Clinician Needs to Know About Juvenile Firesetters. Psychiatr Serv 53:1237–1238PubMedCrossRefGoogle Scholar
  122. 122.
    Coccaro EF (2000) Intermittent Explosive Disorder. CNS Drugs 2:67–71Google Scholar
  123. 123.
    Sheard MH, Marini JL, Bridges CI, et al. (1976) The effect of lithium on impulse aggressive behavior in man. Am J Psychiatry 133:1409–1413PubMedGoogle Scholar
  124. 124.
    Campbell M, Small AM, Green WH, et al. (1984) Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 41:650–656PubMedGoogle Scholar
  125. 125.
    Campbell M, Adams PB, Small AM, et al. (1995) Lithium in hospitalized aggressive children with conduct disorder: a double blind and placebo controlled study. J Am Acad Child Adolesc Psychiatry 34:445–453PubMedCrossRefGoogle Scholar
  126. 126.
    Malone RP, Bennett DS, Luebbert JF, et al. (1998) Aggression classification and treatment response. Psychopharmacol Bull 34:41–45PubMedGoogle Scholar
  127. 127.
    Malone RP, Delaney MA, Luebbert JF, et al. (2000) A double blind and placebo controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 57:649–654PubMedCrossRefGoogle Scholar
  128. 128.
    Lindenmayer JP, Kotsaftis A (2000) Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 61:123–128PubMedGoogle Scholar
  129. 129.
    Hollander E, Swann AC, Coccaro EF, et al. (2005) Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 162(3):621–624PubMedCrossRefGoogle Scholar
  130. 130.
    Hollander E, Tracy KA, Swann AC, et al. (2003) Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28(6):1186–1197PubMedGoogle Scholar
  131. 131.
    Foster HG, Hillbrand M, Chi CC (1989) Efficacy of carbamazepine in assaultive patients with frontal lobe dysfunction. Prog Neuropsychopharmacol Biol Psychiatry 13:865–874PubMedCrossRefGoogle Scholar
  132. 132.
    Mattes JA (1984) Carbamazepine for uncontrolled rage outbursts. Lancet II:1164–1165CrossRefGoogle Scholar
  133. 133.
    Barratt ES, Stanford MS, Felthous A, et al. (1997) The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 17:341–349PubMedCrossRefGoogle Scholar
  134. 134.
    Stanford MS, Houston RJ, Mathias CW, et al. (2001) A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. Psychiatry Res 103:193–203PubMedCrossRefGoogle Scholar
  135. 135.
    Coccaro EF, Kavoussi RJ (1997) Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 54:1081–1088PubMedGoogle Scholar
  136. 136.
    Greendyke RM, Kanter DR (1986a) Therapeutic effects of Pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry 47:423–426Google Scholar
  137. 137.
    Greendyke RM, Kanter DR, Schuster DB, et al. (1986b) Propranolol treatment of assaultive patients with organic brain disease. J Nerv Ment Dis 174:290–294CrossRefGoogle Scholar
  138. 138.
    Kemph JP, DeVane CL, Levin GM, et al. (1993) Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Cild Adolesc Psychiatry 32:577–581CrossRefGoogle Scholar
  139. 139.
    Buitelaar JK, Van der Gaag RJ, Cohen-Kettenis P, et al. (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239–248PubMedCrossRefGoogle Scholar
  140. 140.
    Findling RL, McNamara NK, Branicky LA, et al. (2001) A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Cild Adolesc Psychiatry 39:509–516CrossRefGoogle Scholar
  141. 141.
    Alpert JE, Spilman MK (1997) Psychotherapeutic approaches to aggressive and violent patients. Psychiat Clin N Am 20:453–471CrossRefGoogle Scholar
  142. 142.
    Edmondson CB, Conger JC (1996) A review of treatment efficacy for individuals with anger problems: conceptual, assessment and methodological issues. Clin Psychol Rev 16:251–275CrossRefGoogle Scholar
  143. 143.
    Schwartz JH (1992) Psychoanalytic psychotherapy for a woman with diagnosis of kleptomania. Hosp Community Psychiatry 43:109–110PubMedGoogle Scholar
  144. 144.
    Burstein A (1992) Fluoxetine-lithium treatment for kleptomania. J Clin Psychiatry 53:28–29PubMedGoogle Scholar
  145. 145.
    SA, Low BL (1996) Treatment of kleptomania with fluvoxamine. Acta Psychiatr Scand 93(4):314–315PubMedCrossRefGoogle Scholar
  146. 146.
    Durst R, Katz G, Knobler HY (1997) Buspirone augmentation of fluvoxamine in the treatment of fluvoxamine in the treatment of kleptomania. J Nerv Ment Dis 185:586–588PubMedCrossRefGoogle Scholar
  147. 147.
    Lepkifker E, Dannon PN, Ziv R, et al. (1999) The treatment of kleptomania with serotonin reuptake inhibithors. Clin Neuropharmacol 22:40–43PubMedCrossRefGoogle Scholar
  148. 148.
    Dannon PN, Ianco I, Grunhaus L (1999) Naltrexone treatment in kleptomanic patients. Hum Psychopharm Clin 14:583–585CrossRefGoogle Scholar
  149. 149.
    Kmetz GF, McElroy SL, Collins DJ (1997) Response of kleptomania and mixed mania to valproate. Am J Psychiatry 154:580–581PubMedGoogle Scholar
  150. 150.
    Kim SW (1998) Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 59:159–164PubMedGoogle Scholar
  151. 151.
    Durst R, Katz G, Teitelbaum A, et al. (2001) Kleptomania: diagnosis and treatment options. CNS Drugs 15:185–195PubMedCrossRefGoogle Scholar
  152. 152.
    Sattar P, Ramaswamy S (2004) Internet gaming addiction. Can J Psychiatry 49(12):869–870PubMedGoogle Scholar
  153. 153.
    Dell’Osso B, Altamura AC, Hadley SJ, Baker B, Hollander E (2006) An open label trial of escitalopram in the treatment of compulsive–impulsive Internet usage disorder. Eur Neuropsychopharmacol 16(S1):82–83CrossRefGoogle Scholar
  154. 154.
    Griffiths MD, Woods RT (2000) Risk factors in adolescence: the case of gambling, videogame playing, and the internet. J Gambl Stud 16(2–3):199–225PubMedCrossRefGoogle Scholar
  155. 155.
    Stein DJ, Black DW, Shapira NA, et al. (2001) Hypersexual Disorder and Preoccupation With Internet Pornography. Am J Psychiatry 158:1590–1594PubMedCrossRefGoogle Scholar
  156. 156.
    Cesnik JA, Coleman E (1989) Use of lithium carbonate in the treatment of autoerotic asphyxia. Am J Psychoter 43:277–285Google Scholar
  157. 157.
    Coleman E, Cesnik J, Moore A, et al. (1992) An exploratory study of the role of psychotropic medications in treatment of sex offenders. J Offend Rehabil 18:75–88CrossRefGoogle Scholar
  158. 158.
    Kruesi MJ, Fine S, Valladres L, et al. (1992) Paraphilias: A double-blind cross-over comparison of clomipramine versus desipramine. Arch Sex Behav 21:587–593PubMedCrossRefGoogle Scholar
  159. 159.
    Emmanuel NP, Lydiard RB, Ballenger JC (1991) Fluoxetine treatment of voyerism. Am J Psychiatry 148:950Google Scholar
  160. 160.
    Kafka MP (1994) Sertraline pharmacotherapyfor paraphilias and paraphilia-related disorders: an open trial. Ann Clin Psychiatry 6:189–195PubMedCrossRefGoogle Scholar
  161. 161.
    Stein DJ, Hollander E, Anthony DT, et al. (1992) Serotonergic medications for sexual obsessions, sexual addiction, and paraphilias. J Clin Psychiatry 53:267–271PubMedGoogle Scholar
  162. 162.
    Fedoroff JP (1993) Serotonergic drugs treatment of deviant sexual interests. Annals Sex Res 6:105–121CrossRefGoogle Scholar
  163. 163.
    Fedoroff JP (1988) Buspirone hydrochloride in the treatment of transvestic feticism. J Clin Psychiatry 49:408–409PubMedGoogle Scholar
  164. 164.
    Fedoroff JP (1992) Buspirone hydrochloride in the treatment of atypical paraphilia. Arch Sex Behav 21:401–406PubMedCrossRefGoogle Scholar
  165. 165.
    Coleman E, Gratzer T, Nesvacil L, et al. (2000) Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study. J Clin Psychiatry 61:282–284PubMedGoogle Scholar
  166. 166.
    Raymond NC, Grant JE, Kim SM, et al. (2002) Treatment of compulsive sexual behavior with naltrexone and serotonin reuptake inhibitors: two case studies. Int Clin Psychopharmacol 17:201–205PubMedCrossRefGoogle Scholar
  167. 167.
    Coleman E (1995) Treatment of compulsive sexual behavior. In: Rosen RC, Leiblum SR (eds) Case Studies in Sex Therapy. Guildford Press, New York, NY, pp 333–349Google Scholar
  168. 168.
    Black DW, Monahan P, Gabel J (1997) Fluvoxamine in the treatment of compulsive buying. J Clin Psychiatry 58:159–163PubMedGoogle Scholar
  169. 169.
    Kim SW (1998) Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 59(4):159–164PubMedGoogle Scholar
  170. 170.
    Ninan PT, McElroy SL, Kane CP, et al. (2000) Placebo controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol 20:363–366CrossRefGoogle Scholar
  171. 171.
    Black DW, Gabel J, Hansen J, et al. (2000) A double-blind comparison of fluvoxamine versus placebo in the treatment of subjects with compulsive buying disorder. Ann Clin Psychiatry 12:205–211PubMedGoogle Scholar
  172. 172.
    Koran LM, Bullock KD, Hartston HJ, et al. (2002) Citalopram treatment of compulsive shopping: an open-label study. J Clin Psychiatry 63(8):704–8PubMedGoogle Scholar
  173. 173.
    Koran LM, Chuong HW, Bullock KD, et al. (2003) Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. J Clin Psychiatry 64(7):793–798PubMedCrossRefGoogle Scholar
  174. 174.
    Phillips KA, Taub SL (1995) Skin picking as a symptom of body dysmorphic disorder. Psychopharmacol Bull 31:289–288Google Scholar
  175. 175.
    Block MR, Elliott M, Thompson H, et al. (2001) Fluoxetine in pathologic skin-picking: open-label and double-blind results. Psychosomatics 42(4):314–319CrossRefGoogle Scholar
  176. 176.
    Kalivas J, Kalivas L, Gilman D, et al. (1996) Sertraline in the treatment of neurotic excoriations and related disorders. Arch Dermatol 132:589–590PubMedCrossRefGoogle Scholar
  177. 177.
    Aronowitz B (2001) Psychotherapies for Compulsive Self-Injurious Behaviors. In: Hollander E, Simeon D (eds) Self-injurious behaviors: assessment and treatment. American Psychiatric Publishing, Inc., Washington, DC, pp 97–117Google Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2006

Authors and Affiliations

  • Bernardo Dell’Osso
    • 1
    • 2
  • A. Carlo Altamura
    • 2
  • Andrea Allen
    • 1
  • Donatella Marazziti
    • 3
  • Eric Hollander
    • 1
  1. 1.Compulsive, Impulsive and Anxiety Disorders Program, Department of PsychiatryMount Sinai School of MedicineNew YorkUSA
  2. 2.Department of Psychiatry, Department of Clinical Sciences “Luigi Sacco”University of MilanItaly
  3. 3.Department of Psychiatry Neurobiology, Pharmacology and BiotechnologyUniversity of PisaItaly

Personalised recommendations